Sewage, Soil, and Silence: The Pharmaceutical Contamination Hidden Inside America's Biosolids Policy
A Fertilizer With a Hidden Ingredient List
Each year, roughly 7 million dry metric tons of biosolids — the semi-solid residue generated by municipal wastewater treatment — are land-applied across American agricultural fields, golf courses, and public green spaces. Promoted by the Environmental Protection Agency and municipal water authorities as a sustainable, nutrient-rich alternative to synthetic fertilizers, biosolids carry a secondary profile that rarely appears in promotional literature: a chemically complex mixture of pharmaceutical compounds, hormonal metabolites, antibiotic residues, and personal care product derivatives that wastewater treatment processes are not designed to fully eliminate.
The regulatory architecture governing this practice dates, in its most essential form, to the EPA's Part 503 rule, finalized in 1993. That framework established pathogen reduction standards and set limits for nine heavy metals. What it did not do — and what three decades of subsequent agency inaction have not corrected — is impose any binding restrictions on the pharmaceutical and endocrine-disrupting chemical load that biosolids routinely carry onto agricultural soil.
The result is a regulatory blind spot of considerable public health consequence, one that soil scientists, environmental epidemiologists, and policy analysts have been documenting with increasing urgency while federal rule-making has remained largely static.
What Wastewater Treatment Cannot Remove
To understand the contamination pathway, it is necessary to understand the limits of the treatment process itself. Municipal wastewater treatment was engineered to address biological oxygen demand, suspended solids, and pathogens. It was not designed as a pharmaceutical extraction system.
Research published over the past two decades has consistently demonstrated that conventional activated sludge treatment — the standard process at most American wastewater facilities — achieves only partial removal of many pharmaceutical compounds. Estrogens, including the synthetic hormone 17α-ethinylestradiol found in oral contraceptives, are incompletely degraded. Antibiotics such as tetracyclines and sulfonamides bind to the organic matter in sludge and concentrate during the dewatering process. Antidepressants, anti-epileptic drugs, and nonsteroidal anti-inflammatory compounds have all been detected in biosolids samples collected from facilities across the United States.
When biosolids are land-applied, these residues do not remain inert. Studies examining agricultural soils treated with biosolids have identified pharmaceutical uptake in plant tissues, including food crops such as lettuce, corn, and soybeans. Leaching into groundwater has been documented in multiple field studies. The persistence of antibiotic compounds in treated soils has been directly associated with elevated levels of antibiotic resistance genes — a finding with implications that extend well beyond individual farm boundaries.
The Regulatory Architecture and Its Omissions
The EPA has not been entirely unaware of these concerns. In 2009, the agency released a report identifying 72 pharmaceuticals and personal care product compounds as candidates for further study in connection with biosolids. In 2019, following litigation from environmental groups, the EPA was compelled by court order to respond to a petition requesting updated biosolids regulations. The agency's response acknowledged that its existing rules did not address many known contaminants but stopped well short of initiating formal rule-making.
Critics argue that this pattern of acknowledgment without action reflects both resource constraints at the agency and sustained political pressure from the agricultural sector and municipal water utilities, both of which have strong financial interests in preserving the land-application pathway. Disposing of biosolids through incineration or landfilling is substantially more expensive than land application, and any regulatory tightening of biosolids standards would shift those costs onto municipalities and, ultimately, ratepayers.
The absence of federal pharmaceutical limits in biosolids also interacts poorly with the broader structure of food safety regulation. The Food and Drug Administration's oversight of food contaminants does not extend to soil inputs in conventional agriculture in any systematic way. There is no federal monitoring program that routinely tests food crops for pharmaceutical residues introduced through biosolids application. The data gaps are, in this sense, partly a consequence of regulatory design: agencies that might act are not required to look, and the absence of surveillance data is then cited as evidence that a problem has not been demonstrated.
What the European Comparison Reveals
The contrast with regulatory approaches in several European Union member states is instructive, if imperfect. Germany, the Netherlands, and Switzerland have either prohibited or sharply restricted agricultural biosolids application, citing precautionary concerns about long-term soil contamination and pharmaceutical residue accumulation. The European Commission's revised Sewage Sludge Directive — currently under development — is expected to introduce contaminant thresholds substantially more comprehensive than those in the existing 1986 framework, with pharmaceutical compounds among the categories under active consideration.
The EU's approach reflects a broader precautionary orientation in environmental regulation that differs philosophically from the risk-based, post-evidence framework more characteristic of American environmental law. Under the precautionary model, the burden falls on demonstrating safety before wide-scale use; under the American framework, restriction typically requires demonstrated harm at a threshold sufficient to justify regulatory action. For slowly accumulating soil contaminants with diffuse exposure pathways, the latter standard creates a structural disadvantage for public health protection.
It is worth noting that the European framework is not without its own limitations. Biosolids land application continues in several EU member states, and enforcement of existing standards varies considerably across national jurisdictions. The comparison is not intended to suggest that European regulation is uniformly superior, but rather that the policy choices embedded in the American framework are choices — not inevitabilities — and that alternative regulatory architectures exist and are being actively developed.
Toward a More Coherent Regulatory Response
Several reform pathways have been proposed by researchers and policy advocates. The most foundational involves directing the EPA to initiate formal rule-making to establish monitoring requirements and, where evidence supports it, concentration limits for pharmaceutical compounds in biosolids intended for land application. This would require either congressional appropriation of dedicated resources or a legal mechanism compelling agency action — neither of which is currently in place.
A parallel track involves strengthening the monitoring infrastructure. Mandatory testing of biosolids at the point of application, combined with soil and crop sampling in areas with documented biosolids histories, would generate the surveillance data currently lacking. Without that data, the evidentiary bar for regulatory action remains artificially elevated.
State-level action has begun to fill some of the federal void. Maine enacted legislation in 2022 restricting biosolids application on land where PFAS contamination had been documented, following the discovery of highly elevated per- and polyfluoroalkyl substance levels on farms with long biosolids application histories. While PFAS and pharmaceuticals represent distinct contaminant categories, Maine's experience illustrates both the scale of potential harm and the capacity of state governments to act when federal frameworks prove inadequate.
The Public Health Stakes
The long-term public health implications of chronic, low-level pharmaceutical exposure through food and soil remain incompletely characterized — a fact that is itself a product of inadequate research investment rather than evidence of safety. What the existing literature does support is that the exposure pathways are real, that current treatment and regulatory systems are not designed to interrupt them, and that the populations bearing the greatest exposure burden — rural agricultural communities, farm workers, and households dependent on private wells near biosolids application sites — are among those with the least political and economic power to demand change.
For a regulatory system that aspires to protect public health on the basis of evidence, the biosolids question presents an uncomfortable challenge: the evidence is sufficient to identify a problem, insufficient to fully quantify it, and the gap between those two conditions has become, in practice, a justification for inaction. Closing that gap will require both scientific investment and the political will to treat precaution as a legitimate basis for regulatory design — not merely a European preference, but a defensible standard for protecting American farmland and the communities that depend on it.
